Pacific Edge to Release Half Year Results on 24 November 2026

Aakashdeep

04 November 2026 10:15 AM AEDT

Pacific Edge to Release Half Year Results on 24 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Pacific Edge (ASX:PEB), a cancer diagnostics company headquartered in Dunedin, New Zealand, has advised that its half year financial results for the six months to 30 September 2026 will be released on Tuesday, 24 November 2026, prior to 10am.

Key Points

Half year results for the six months to 30 September 2026 to be released on 24 November 2026, prior to 10am
An Investor and Analyst conference call will follow at 11:00am NZST on the same day
The investor briefing will be available via webcast and phone with a Conference ID of 2639914
The filing was approved for release by Chief Financial Officer Grant Gibson

Half Year Results Release Date and Timing

Pacific Edge disclosed on 4 November 2026 that its interim financial result for the six months ending 30 September 2026 will be released on Tuesday, 24 November 2026, prior to 10am. The company, which is dual listed on the NZX and ASX, develops and commercialises bladder cancer diagnostic and prognostic tests under its Cxbladder suite. The release was approved by Grant Gibson, the company's Chief Financial Officer.

Investor and Analyst Conference Call Details

Following the results release, Pacific Edge will host an Investor and Analyst conference call at 11:00am New Zealand Standard Time on 24 November 2026. The briefing will be accessible via webcast and by phone using toll-free numbers provided for callers in New Zealand, Australia, and the United States and Canada. Participants will use Conference ID 2639914 to access the call. Questions may be submitted online in writing via the webcast platform or verbally via the audio call system when prompted.

Company and Cxbladder Test Overview

Pacific Edge is a global cancer diagnostics company providing its suite of Cxbladder tests through wholly owned, CLIA-certified laboratories in New Zealand and the United States. Cxbladder is a suite of non-invasive genomic urine tests for risk stratification of urothelial cancer. The filing states Cxbladder Triage is included in the American Urological Association's Microhematuria Guideline. In the United States, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. Cxbladder is available in the US, Australasia, Israel, and markets throughout Asia and South America.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.